A Controlled Trial Comparing the Efficacy of Aerosolized Pentamidine and Parenteral/Oral Trimethoprim-Sulfamethoxazole in the Treatment of Pneumocystis Pneumonia in AIDS

Inclusion Criteria

Prior Medication:

Allowed:

• Zidovudine (AZT), but must be suspended during study medication.

Unequivocal diagnosis of Pneumocystis carinii pneumonia established by morphologic confirmation of three or more typical Pneumocystis carinii organisms in sputum, bronchoalveolar lavage fluid, or lung tissue obtained by transbronchial or open-lung biopsy within 3 days before or after randomization. If morphologic confirmation is not possible prior to therapy, patients may be randomized if the investigator believes there is a high suspicion of PCP based on clinical presentation. If morphologic diagnosis cannot be established within 5 days of randomization, the patient will be withdrawn from study therapy. Resting (A-a) DO2 less than 30 torr on room air at all ACTG sites except San Francisco General Hospital. Non-ACTG sites will enter patients up to a resting (A-a) DO2less than 55 mmHg on room air.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Dyspnea, cough, bronchospasm, or other reasons causing inability to cooperate with aerosol administration.
• History of major adverse reaction to pentamidine or sulfonamide-containing preparation defined as:
• Absolute neutropenia of 750 or less PMN + bands cells/mm3.
• Thrombocytopenia below 40000 platelets/mm3.
• Rise in creatinine:
• To more than 3.0 mg/dl.
• Liver function abnormalities:
• SGOT or SGPT greater than 5 x upper limit of normal.
• Hypoglycemia below 50 mg/dl.
• Rash:
• Exfoliative or mucositis.
• Cough:
• Unremitting or bronchospasm uncontrolled by bronchodilator preventing more than 50 percent of delivered dose for more than 2 days.

Concurrent Medication:

Excluded:

• Other drugs for the treatment or prevention of AIDS or Pneumocystis carinii pneumonia.
• Zidovudine (AZT).

Patients with the following are excluded:

• Dyspnea, cough, bronchospasm, or other reasons causing inability to cooperate with aerosol administration.
• History of major adverse reaction to pentamidine or sulfonamide-containing preparation defined as:
• Absolute neutropenia of 750 or less PMN + bands cells/mm3.
• Thrombocytopenia lower than 40000 platelets/mm3.
• Rise in creatinine:
• To greater than 3.0 mg/dl.
• Liver function abnormalities:
• SGOT or SGPT greater than 5 x upper limit of normal.
• Hypoglycemia less than 50 mg/dl.
• Rash:
• Exfoliative or mucositis.
• Cough:
• Unremitting or bronchospasm uncontrolled by bronchodilator preventing more than 50 percent of delivered dose for more than 2 days.

Prior Medication:

Excluded within 14 days of study entry:

• Systemic steroids higher than adrenal replacement doses.
• Excluded within 6 weeks of study entry:
• Another antiprotozoal regimen for this episode, whether therapeutic or prophylactic.
• Sulfamethoxazole / trimethoprim.
• Pyrimethamine.
• Sulfadoxine / pyrimethamine.
• Pentamidine.
• Eflornithine.

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety